Clover Reports Dosing of SCB-808 (biosimilar, etanercept) in P-III Trial in China


  • The P-III study involves assessing of SCB-808 vs Enbrel in patients with AS (axSpA) via SC administration
  • SCB-808 is being developed in the prefilled syringe formulation which is ready for injection and can be self-administered by the patients, thus overwhelming the current Enbrel biosimilar which are available in lyophilized powder formulation in China
  • Clover has new state-of-the-art 35,000m2 cGMP biomanufacturing facility, with initial 2 x 2,000L bioreactor capacity and further expandable to address the unmet medical needs of Chinese patients suffering from autoimmune diseases

Click here to read full press release/ article | Ref: Clover | Image: Signbox